GONADOTROPIN-RELEASING HORMONE RECEPTOR

Approval Year

Substance Class	Protein Created by `admin` on `Sat Dec 16 12:11:56 GMT 2023` Edited by `admin` on `Sat Dec 16 12:11:56 GMT 2023`
Protein Type	RECEPTOR
Protein Sub Type
Sequence Origin	HUMAN
Sequence Type	COMPLETE
Record UNII	MJK4KMT12V
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

GONADOTROPIN-RELEASING HORMONE RECEPTOR

Common Name

English

GRHR

Common Name

English

GNRH RECEPTOR

Common Name

English

Code System Code Type Description

FDA UNII

MJK4KMT12V

Created by admin on Sat Dec 16 12:11:59 GMT 2023 , Edited by admin on Sat Dec 16 12:11:59 GMT 2023

PRIMARY

From	To
1_114	1_196

Glycosylation Type

HUMAN

Glycosylation Link Type	Site
N	1_18
N	1_102

Related Record Type Details


					EFY6W0M8TG

LEUPROLIDE

AGONIST -> TARGET

Amount:


					OON1HFZ4BA

CETRORELIX

INHIBITOR -> TARGET

Amount:


					H50H3S3W74

HISTRELIN

AGONIST -> TARGET

Amount:


					56S17Z6X9M

SUFUGOLIX

INHIBITOR -> TARGET

Comments:

BINDING

Interaction Type:

NON-COMPETITIVE

Qualification:

IC50

Amount:


					W486SJ5824

ABARELIX

INHIBITOR -> TARGET


					P76B05O5V6

RELUGOLIX

INHIBITOR -> TARGET

Amount:


					UJ8NQ5Z0VX

PEFORELIN

AGONIST -> TARGET

Amount:


					Q1IF8M2YL3

OZARELIX

INHIBITOR -> TARGET

Amount:


					2N7D33X56N

AZAGLY-NAFARELIN

AGONIST -> TARGET

Amount:


					PXW8U3YXDV

BUSERELIN

AGONIST -> TARGET

Amount:


					9081Y98W2V

TRIPTORELIN

AGONIST -> TARGET


					66VRX9TN9T

BAY-1214784

INHIBITOR -> TARGET

Amount:


					9O7312W37G

GONADORELIN

AGONIST -> TARGET

Amount:


					7981LI6QXL

RAMORELIX

INHIBITOR -> TARGET

Amount:


					7CDW97HUEX

LINZAGOLIX

INHIBITOR -> TARGET

Amount:


					TKG3I66TVE

DESLORELIN

AGONIST -> TARGET

Amount:


					1X0094V6JV

NAFARELIN

AGONIST -> TARGET

Amount:


					IX503L9WN0

GANIRELIX

INHIBITOR -> TARGET

Amount:


					0F65R8P09N

GOSERELIN

AGONIST -> TARGET

Amount:


					Q041AO6T91

FERTIRELIN

AGONIST -> TARGET

Amount:


					05ME7P8ZBJ

DETIRELIX

INHIBITOR -> TARGET

Amount:


					D19V7048JK

TEVERELIX

INHIBITOR -> TARGET

Amount:


					68HX54O1VL

PRAZARELIX

INHIBITOR -> TARGET

Amount:


					VQ6CK0CITA

OPIGOLIX

INHIBITOR -> TARGET

Amount:


					SX0XJI3A11

DEGARELIX

INHIBITOR -> TARGET

Amount:


					ZD8NZ8J5LN

LECIRELIN

AGONIST -> TARGET

Comments:

Agonists do not quickly dissociate from the GnRH receptor. As a result, initially there is an increase in FSH and LH secretion (so-called "flare effect"). Levels of LH may increase by up to 10-fold,[15][16] while levels of testosterone generally increase to 140 to 200% of baseline values. However, after continuous administration, a profound hypogonadal effect (i.e. decrease in FSH and LH) is achieved through receptor downregulation by internalization of receptors. Generally this induced and reversible hypogonadism is the therapeutic goal.

Amount:


					94055UOQ3Y

ITURELIX

INHIBITOR -> TARGET

Amount:


					5B2546MB5Z

ELAGOLIX

INHIBITOR -> TARGET

Qualification:

IC50

Amount:

Name	Property Type	Amount	Referenced Substance	Defining	Parameters	References
MOL_WEIGHT	CHEMICAL
Molecular Formula	CHEMICAL